We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

A Closer Look At The sDNA Posters Featured at ACG 2015

As we announced Monday, data supporting Exact Sciences' stool DNA (sDNA) screening platform for colorectal cancer will be presented in three posters at the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2015), taking place this week in Honolulu.

In addition to the details we shared in the release, you can view key charts and tables from the posters with a short summary below.

Colorectal Cancer Screening with Multi-target stool DNA-based Testing Previous Screening History of the Initial Patient Cohort

The first poster shows that a clinically significant proportion of initial Cologuard users, 42 percent, age 50-74, the primary target age for screening, reported no previous colorectal cancer screening, while 36 percent of users overall were similarly unscreened previously.

These data suggest that the availability of Cologuard as a screening option may help increase the number of patients who get screened.

Table-2-Final-Patient-History

Multi-target stool DNA based Colorectal Screening Modeling the Impact of Inter-test Interval on Clinical Effectiveness

In a second poster, researchers looked at the decrease in colorectal cancer incidence and colorectal cancer death with sDNA screening compared to colonoscopy at various intervals.

The study found that screening with Cologuard at three-year intervals could reduce colorectal cancer death by 67 percent.

Preferences for Colorectal Screening Tests Among a Previously Unscreened Population

In a third poster, a newly completed patient preference study, corroborating the finding of the two previously published preference studies, finds that screen-naïve patients, who intend to be screened within the next year, prefer colonoscopy (40 percent) and multi-target sDNA (35 percent) significantly more often than FOBT or FIT (9-10 percent) or flexile sigmoidoscopy (4 percent).

There was no significant preference difference between colonoscopy and multi-target sDNA, but the difference between colonoscopy and multi-target sDNA compared to the other three tests was significant.

ACG-Poster-Figure-2-101615_blank

For more information on the posters and ACG 2015, please read our press release

 

Topics: Exact Sciences News

Subscribe To The Blog